A key challenge for TKIs (including those targeting EGFR) in cancer is the development of acquired resistance, with many patients showing disease progression not long after the initial response (Wagle et al, 2011; Lovly and Shaw, 2014). The gene discussed is EGFR; the disease is cancer.